title: Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction.
abstract: Increased levels of plasminogen activator inhibitor (PAI) have recently been described in patients with acute myocardial infarction (AMI). To correlate PAI levels to patency of infarct arteries after thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA), 125 consecutive patients with AMI were examined. Blood levels of fibrinogen, plasminogen, tissue plasminogen activator (t-PA) and PAI were measured before treatment initiation, 10 minutes after completion of rt-PA infusion and 24 and 48 hours after treatment. Coronary angiography, performed in all patients 72 hours after beginning rt-PA infusion, revealed patent infarct arteries in 97 patients and occluded infarct arteries in 28 patients. Pretreatment levels of PAI were significantly higher in patients with occluded infarct arteries (18.0 +/- 11.5 vs 10.5 +/- 9.3 IU/ml, p less than 0.01). Conceivably, higher levels of PAI may interfere with the natural thrombolytic process and make pharmacologic thrombolytic intervention less effective.
authors.affiliation: Cardiology Institute, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.
authors.forename: G I
authors.initials: GI
authors.lastname: Barbash
authors.forename: H
authors.initials: H
authors.lastname: Hod
authors.forename: A
authors.initials: A
authors.lastname: Roth
authors.forename: H I
authors.initials: HI
authors.lastname: Miller
authors.forename: S
authors.initials: S
authors.lastname: Rath
authors.forename: Y H
authors.initials: YH
authors.lastname: Zahav
authors.forename: M
authors.initials: M
authors.lastname: Modan
authors.forename: A
authors.initials: A
authors.lastname: Zivelin
authors.forename: S
authors.initials: S
authors.lastname: Laniado
authors.forename: U
authors.initials: U
authors.lastname: Seligsohn
mesh_terms: D001158:Arteries / Q000503:physiopathology; D005340:Fibrinogen / Q000032:analysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D010958:Plasminogen / Q000032:analysis; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors*; D015849:Plasminogen Inactivators; D010959:Tissue Plasminogen Activator / Q000097:blood; D014654:Vascular Patency
chemical_list: D005343:Fibrinolytic Agents; D015849:Plasminogen Inactivators; D005340:Fibrinogen; D010958:Plasminogen; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator